Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Recurrent Urinary Tract Infection
NCT03050515Phase 1Completed
- Sponsor
- University of California, Irvine
- Start
- Feb 2018
- Primary completion
- Jun 2019
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic fecal microbiota in urinary tract infection (UTI), sponsored by University of California, Irvine. Primary endpoint: Change in frequency of culture proven urinary tract infections at 6 months. Started Feb 2018; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT03050515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03050515.